Gene therapy developer Renovacor, a Temple University spinout, has secured series A funding from investors including Novartis Venture Fund.

Renovacor, a US-based gene therapy spinout of Temple University focused on cardiovascular disease, closed an $11m series A round yesterday co-led by Novartis Venture Fund, the corporate venturing vehicle for drug maker Novartis. Broadview Ventures, a cardiovascular-focused impact investment unit formed by family office Leducq Family Trust, and BioAdvance co-led the round, with contributions from…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.